IDEXX Laboratories, Inc. (NASDAQ:IDXX) VP Giovani Twigge sold 14,750 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $250.51, for a total value of $3,695,022.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
IDXX opened at $251.30 on Tuesday. The stock has a fifty day moving average of $265.77 and a 200-day moving average of $270.95. The firm has a market capitalization of $21.58 billion, a P/E ratio of 58.99 and a beta of 0.73. IDEXX Laboratories, Inc. has a 12-month low of $176.11 and a 12-month high of $294.57. The company has a quick ratio of 0.80, a current ratio of 1.12 and a debt-to-equity ratio of 3.76.
IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $1.24 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.10. The company had revenue of $605.30 million during the quarter, compared to analyst estimates of $597.09 million. IDEXX Laboratories had a return on equity of 405.71% and a net margin of 17.99%. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.05 earnings per share. On average, analysts expect that IDEXX Laboratories, Inc. will post 4.76 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on IDXX shares. Credit Suisse Group raised their price objective on IDEXX Laboratories from $282.00 to $293.00 and gave the stock an “outperform” rating in a research note on Friday, August 16th. Zacks Investment Research lowered IDEXX Laboratories from a “hold” rating to a “sell” rating and set a $267.00 price objective for the company. in a research note on Monday, November 11th. ValuEngine lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Guggenheim set a $310.00 price objective on IDEXX Laboratories and gave the stock a “buy” rating in a research note on Friday, November 1st. Finally, Goldman Sachs Group initiated coverage on IDEXX Laboratories in a report on Monday, September 9th. They issued a “neutral” rating and a $277.00 target price for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $289.57.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Further Reading: Benefits of owning preferred stock
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.